Genmab — Februar 2023

Solsen

Side 26 https://www.novartis.com/sites/novartis_com/files/q4-2022-investor-presentation.pdf udviklingen i salget af Kesimpta ligner mest af alt en omsætning på $1,8 bn i 2023. Det giver 1,2-1,3 mia dkk til Genmabs bundlinie

Bulder

Ja, sc ocrevus når ikke på markedet i 23

Bulder

Bliver interessant om sc ocr kan tages hjemme. 6 mdr er en klar fordel fremfor månedligt.

Solsen

Halozyme venter approval i 2024 og topsales i +$8 bn på Ocrevus. Siderne 18-20 i denne fra Halozymes er interessant https://s28.q4cdn.com/284259014/files/doc_presentation/2023/01/Halo_Investor_Deck_FINAL-v2.pdf

Solsen

Jeg har ikke set lægebedømmelser. Men Kesimpta har en klar fordel ved ikke at nedkæmpe alle b-celler, hvorfor pts på Kesimpta er bedre rustet imod infektioner og vira pga at pts eget immunforsvar er bedre end ved Ocrevus behandling. Men kender ikke hvor megen vægt det har i konkurrencen.

Solsen

Men $8bn er voldsomt og noget Novartis kan kæmpe om.

Bulder

Det er 14,5 mia dara i 28 også, og ingen konkurrence, kun egne kombinationer.

Solsen

Ja det er utroligt flotte tal. De må være stolte i Genmab.

Solsen

De $14,5 bn giver vel 15 mia dkk til Genmab iflg hurtig hovedregning. Den voldgift bliver spændende

Bulder

For de penge kan man købe 10 fabrikker

E_L

we haven't seen any Symphony Health data

for Dara again in Jan, or have we ?

Bulder

No, I Think Helge’s source dryed out.

E_L

it's a shame, makes it even harder to judge Dara. Would like to know if Januari was good; JNJ mentioned something about austerity being an issue for some of their pharma sales; i wonder if some buyers delayed inventory buying in december to 2023 so that the costs didn't show up in 2022

E_L

another issue could have been the price hike in september; this could have led to buyers buying before the hike for Q4 to reduce cost, thereby inflating the Q3 number which may have led to Genmab raising the forecast

E_L

but we'll probably never find out

E_L

meanwhile 10yr bund yields dropping over 20 basis points, but we don't seem to benefit from that anymore...

E_L

Teprotumumab
improves dry eye symptoms https://onlinelibrary.wiley.com/doi/10.1111/ceo.14208

Solsen

Perhaps 2540 dkk could be the floor according to Thenote

E_L

2595
is 50% back from the 1863 - 3327 rally

Solsen

Could be right.